Cure8 research brief
People with PSC who undergo liver transplant — especially those who have IBD at the time of transplant — remain at elevated risk for colorectal neoplasia, IBD flare or new-onset IBD, and for PSC recurrence. Knowing this affects post-transplant surveillance and follow-up care.
Adults with PSC and IBD, clinicians managing post-liver-transplant care (hepatologists, gastroenterologists, transplant teams), and researchers studying PSC-IBD outcomes.
This systematic review and meta-analysis (34 studies, 3,828 patients; searches through June 2025) estimated incidence rates after LTx for PSC.
Key outcomes included pooled incidence rates for IBD exacerbation, colectomy for refractory disease, colorectal neoplasia (including advanced neoplasia), de novo IBD in previously PSC-only patients, and PSC recurrence. The authors found higher PSC recurrence in patients who had IBD at the time of transplant compared with PSC-only patients.
Clinical implications The findings support continued endoscopic surveillance (colonoscopy) and close monitoring of IBD activity after liver transplant for PSC. Teams caring for these patients should be alert to new or worsening gastrointestinal disease and colorectal neoplasia risk.
Source and scope note This brief is grounded in the article abstract from a peer-reviewed transplant journal reporting a systematic review and meta-analysis; it summarizes the reported pooled incidence estimates and conclusions but does not add results beyond the abstract.
This classification and summary are based on the article abstract (systematic review and meta-analysis) published in Transplantation; pooled incidence rates come from studies up to June 2025. The full text may have additional details on study heterogeneity and limitations that inform interpretation.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
People with ulcerative colitis face long-term health risks beyond the gut. This study suggests that getting a colectomy early after diagnosis might be linked to lower long-term risk of cardiovascular disease and type 2...
CDI is a common and important complication in people with IBD; which antibiotic is used can affect recurrence risk and subsequent need for surgery. This review pools available studies and suggests vancomycin may reduce...
CDI is a common and serious complication in people hospitalized with IBD. Understanding whether CDI independently increases the risk of death, ICU care, or surgery — or mainly drives longer stays and higher costs — helps...
